Stock AnalizSilence Therapeutics plc SLN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Silence Therapeutics plc (SLN) is a healthcare company listed in the US with a market value of about $1.2B. In the twelve months to June 30, 2026 it had revenue of $615000 and net income of -$60M, a net margin of -9748.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -40% a year, a 5-year average ROIC of -197%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $615000 | $559000 | $43M | $32M | $22M | $17M | $7M | $322180 | — |
| Net income | -$60M | -$89M | -$45M | -$54M | -$50M | -$53M | -$44M | -$26M | -$24M |
| Free cash flow | -$42M | -$62M | -$68M | -$50M | -$57M | $7M | -$15M | $2M | -$22M |
| EPS (diluted) | $-1.27 | $-1.43 | $-0.73 | $-0.87 | $-0.81 | $-0.85 | $-0.71 | $-0.42 | $-0.38 |
| Net margin | -9748.5% | -15851.9% | -104.7% | -171.4% | -232.4% | -317.4% | -614.1% | -8025.4% | — |
| ROIC | — | -115.2% | -37.3% | -227.7% | -177.2% | -428.9% | -357.3% | -93.1% | -52.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $19.75, 0% below the current price; targets range from $19.00 to $20.00; the consensus rating is “Hold”; expected EPS is $-0.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Silence Therapeutics pay a dividend?
Not currently.
Is Silence Therapeutics a good stock to buy?
We do not give buy or sell advice. Silence Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.